<DOC>
	<DOCNO>NCT00726596</DOCNO>
	<brief_summary>This phase II trial study well hydroxychloroquine work treat patient previously treat prostate cancer . Autophagy destroy protein substance cell may use prostate cancer cell survive . Hydroxychloroquine , block autophagy , may slow growth possibly kill prostate cancer cell .</brief_summary>
	<brief_title>Hydroxychloroquine Treating Patients With Rising PSA Levels After Local Therapy Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>Inclusion Criteria Histologically proven stage D0 prostate cancer ( i.e. , tumor originally diagnose limited prostate ) D1 prostate cancer ( metastatic regional lymph node ) rise PSA value definitive local therapy . Must undergone local treatment via prostatectomy radiation therapy . Must PSA progression local treatment : 1 . PSA value patient surgery must &gt; 0.2 ng/mL , determine two measurement , least 1 month apart least 6 month prostatectomy 2 . PSA value patient radiation must ≥ 2.0 ng/ml great nadir achieve radiation , determine two measurement 1 month apart least 6 month radiation treatment complete . ( Patients receive adjuvant salvage radiation prostatectomy must PSA &gt; 0.2 ) 3 . The first two PSA value ( 5.1.3a 5.1.3b ) , along third ( study baseline ) value must rise ( i.e. , must overall rise trajectory , third value lower first value ) . Baseline bone scan CT abdomen/pelvis demonstrate metastatic disease . Age ≥ 18 year Estimated life expectancy least 6 month . ECOG performance status &lt; 2 . ( see Appendix B ) A WBC &gt; 3500/μl , ANC &gt; 1500/μl , hemoglobin &gt; 10 g/dl , platelet count &gt; 100,000/μl require . Adequate renal function ( serum creatinine &lt; 1.5 mg/dL creatinine clearance &gt; 50 ml/min ) . Total bilirubin must within 1.5X normal institutional limit . If total bilirubin outside normal institutional limit , ass direct bilirubin . The direct bilirubin must within normal parameter . Transaminases ( SGOT and/or SGPT ) must less 2.5X institutional upper limit normal . Documented ophthalmic exam within last twelve month demonstrate evidence retinopathy . Patients retinal change consider enrollment write clearance board certify ophthalmologist . Must serum total testosterone level ≥150 ng/dL time enrollment within 4 week prior randomization . Must sign inform consent . Exclusion Criteria Serious concomitant systemic disorder would compromise safety patient compromise patient 's ability complete study , discretion investigator . Must ADT neoadjuvant , adjuvant and/or salvage set least 3 month testosterone level &gt; 150 ng/dl . Second primary malignancy except situ carcinoma ( e.g . adequately treat nonmelanomatous carcinoma skin ) malignancy treat least 5 year previously evidence recurrence . Rheumatoid arthritis systemic lupus erythematosus treatment . Psoriasis . Receiving diseasemodifying antirheumatic drug ( DMARD ) . Active clinically significant infection require antibiotic . G6PD deficiency . Taking commercially available medication may theoretically either stimulate inhibit autophagy , calcitriol chloroquine . Taking medication may lead interaction hydroxychloroquine , include penicillamine , telbivudine , botulinum toxin , digoxin , propafenone . Must visual field change prior 4aminoquinoline compound use . Must take hydroxychloroquine treatment prophylaxis malaria . History hypersensitivity 4aminoquinoline compound .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>Prostate-Specific Antigen</keyword>
</DOC>